Connect with us

Technology

HONEYWELL BOARD OF DIRECTORS APPROVES SPIN-OFF OF HONEYWELL AEROSPACE

Published

on

Spin-off distribution is expected to occur on June 29, 2026Honeywell Aerospace will be a leading global tier-1 aerospace and defense supplier of mission critical systems and technologiesHoneywell Technologies will be a global leader of the industrial world’s transition from automation to autonomy

CHARLOTTE, N.C., June 15, 2026 /PRNewswire/ — Honeywell (NASDAQ: HON) today announced that its Board of Directors has formally approved the planned spin-off of Honeywell Aerospace. This approval represents a significant milestone in the separation process, which remains on track for completion on June 29, 2026. Following the completion of the spin-off, the remaining pure-play automation company will be known as Honeywell Technologies.

At 12:01 a.m. New York City time on June 29, 2026 (the “Distribution Date”), Honeywell will distribute all of the issued and outstanding shares of Honeywell Aerospace common stock pro rata to Honeywell shareowners of record on June 15, 2026 (the “Record Date”), on the basis of one share of Honeywell Aerospace common stock for every two shares of Honeywell common stock held as of the close of business on the Record Date. The distribution is subject to the satisfaction or waiver of certain conditions, as set forth in the form of Separation and Distribution Agreement filed with the U.S. Securities and Exchange Commission (“SEC”) as part of Honeywell Aerospace’s registration statement on Form 10, which was declared effective by the SEC on June 11, 2026.

“Today’s announcement clears the path to establishing two independent industry leaders in Honeywell Aerospace and Honeywell Technologies and also reflects our significant portfolio transformation over the past three years,” said Vimal Kapur, Chairman and CEO of Honeywell. “With clear strategies and growth drivers that build on Honeywell’s century-long legacy, we are confident that both companies will be well-positioned to maximize long-term value for customers, employees and shareowners.”

Honeywell Aerospace common stock is expected to begin trading on the Nasdaq Stock Market LLC (“Nasdaq”) under the ticker symbol “HONAV” on a “when-issued” basis on or about June 15, 2026.  Honeywell Aerospace common stock is expected to begin “regular-way” trading on Nasdaq under the ticker symbol “HONA” on June 29, 2026. Following the separation, Honeywell Technologies will continue to trade on the Nasdaq under the ticker “HON.”

Beginning on or about June 15, 2026 and continuing through June 26, 2026, it is expected that there will be two markets in Honeywell common stock on Nasdaq:  a “regular-way” market under Honeywell’s current ticker symbol “HON”, in which Honeywell shares will trade with the right to receive shares of Honeywell Aerospace common stock on the Distribution Date, and an “ex distribution” market under the ticker symbol “HONIV”, in which Honeywell shares will trade without the right to receive shares of Honeywell Aerospace common stock on the Distribution Date.

As previously announced, a 1-for-2 reverse stock split of Honeywell Technologies common stock will immediately follow the spin-off along with a proportionate reduction in the Company’s number of authorized shares of common stock, subject to and contingent on the completion of the Honeywell Aerospace spin-off.

About Honeywell

Honeywell is an integrated operating company serving a broad range of industries and geographies around the world, with a portfolio that is underpinned by our Honeywell Accelerator operating system and Honeywell Forge platform. As a trusted partner, we help organizations solve the world’s toughest, most complex challenges, providing actionable solutions and innovations for aerospace, building automation, industrial automation, process automation, and process technology that help make the world smarter and safer as well as more sustainable.

Additional Information

Honeywell uses our Investor Relations website, www.honeywell.com/investor, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD.  Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts, and social media.

Forward-Looking Statements

Certain statements in this release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements are those that address activities, events, or developments that management intends, expects, projects, believes, or anticipates will or may occur in the future.  They are based on management’s assumptions and assessments in light of past experience and trends, current economic and industry conditions, expected future developments, and other relevant factors, many of which are difficult to predict and outside of our control.  They are not guarantees of future performance, and actual results, developments and business decisions may differ significantly from those envisaged by our forward-looking statements.  We do not undertake to update or revise any of our forward-looking statements, except as required by applicable securities law.  Our forward-looking statements are also subject to material risks and uncertainties, including ongoing macroeconomic and geopolitical risks, such as changes in or application of trade and tax laws and policies, including the impacts of tariffs and other trade barriers and restrictions, lower GDP growth or recession in the U.S. or globally, supply chain disruptions, capital markets volatility, inflation, and certain regional conflicts, that can affect our performance in both the near- and long-term.  In addition, no assurance can be given that any plan, initiative, projection, goal, commitment, expectation, or prospect set forth in this release can or will be achieved.  Some of the important factors that could cause Honeywell’s actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to:  (i) the ability of Honeywell to effect the spin-off transaction described above and to meet the conditions related thereto; (ii) the possibility that the spin-off transaction will not be completed within the anticipated time period or at all; (iii) the possibility that the spin-off transaction will not achieve its intended benefits; (iv) the impact of the spin-off transaction on Honeywell’s businesses and the risk that the spin-off transaction may be more difficult, time-consuming or costly than expected, including the impact on Honeywell’s resources, systems, procedures and controls, diversion of management’s attention and the impact and possible disruption of existing relationships with regulators, customers, suppliers, employees and other business counterparties; (v) the possibility of disruption, including disputes, litigation or unanticipated costs, in connection with the spin-off transaction; (vi) the uncertainty of the expected financial performance of Honeywell or Honeywell Aerospace following completion of the spin-off transaction; (vii) negative effects of the announcement or pendency of the spin-off transaction on the market price of Honeywell’s securities and/or on the financial performance of Honeywell; (viii) the ability to achieve anticipated capital structures in connection with the spin-off transaction, including the future availability of credit and factors that may affect such availability; (ix) the ability to achieve anticipated tax treatments in connection with the spin-off transaction and future, if any, divestitures, mergers, acquisitions and other portfolio changes and the impact of changes in relevant tax and other laws; (x) the failure to realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with the spin-off transaction and completed and future, if any, divestitures, mergers, acquisitions, and other portfolio management, productivity and infrastructure actions; and (xi) the possibility that the reverse stock split and authorized share reduction will not be completed within the anticipated time period or at all, including due to a failure of the spin-off transaction to occur.  These forward-looking statements should be considered in light of the information included in this release, our Form 10-K and other filings with the SEC.  Any forward-looking plans described herein are not final and may be modified or abandoned at any time.

Honeywell Contacts:

Media

Investor Relations

Stacey Jones

Mark Macaluso

(980) 378-6258

(704) 627-6118

Stacey.Jones@honeywell.com

Mark.Macaluso@honeywell.com

Honeywell Aerospace Contacts:

Media

Investor Relations

Brian Grace

Sean Meakim

(602) 897-0205

(704) 627-6200

Brian.Grace@HoneywellAerospace.us

Sean.Meakim@HoneywellAerospace.us

 

View original content:https://www.prnewswire.com/news-releases/honeywell-board-of-directors-approves-spin-off-of-honeywell-aerospace-302799898.html

SOURCE Honeywell

Continue Reading

Technology

SQAIRZ Launches SQAIRZ Medical

Published

on

By

New Division Introduces the First Integrated Balance & Stability Platform to Help Combat Fall Risk and Support Lifelong Movement, Vitality and Independence

WINDHAM, N.H., Sept. 10, 2026 /PRNewswire/ — SQAIRZ, the biomechanically driven performance footwear company built on the belief that performance starts where you stand, today announced the launch of SQAIRZ Medical, extending the company’s expertise in stability and human movement into one of the most significant health challenges facing an aging population: fall risk and the loss of mobility, vitality and independence that can follow.

At the center of the new division is SENTRX™ purpose-built Balance & Stability footwear engineered from the ground up by SQAIRZ to help create a more stable foundation for everyday movement. In addition, SQAIRZ Medical has developed a holistic clinical framework designed to provide a critical continuum of support.

That framework integrates a Balance & Stability Protocol that connects objective fall-risk assessment, SQAIRZ’s biomechanically engineered footwear, individualized clinical intervention, and ongoing outcomes tracking into a single approach that optimizes support at every stage of the balance and stability journey.

The need is urgent. One in four U.S. adults over age 65 falls at least once every year. For adults over 80, the risk increases to one in two. Fall-related injuries account for more than $80 billion in annual U.S. healthcare spending, while also diminishing an individual’s ability to fully engage in the relationships and experiences that define quality of life.

“For more than a decade, SQAIRZ has studied the relationship between the ground, the foot, stability and human performance,” said Bob Winskowicz, Founder and CEO of SQAIRZ. “SQAIRZ Medical represents the next evolution of that work. We believe that better stability should not only help an athlete perform better. It can help people continue living better. Our goal is to identify risk earlier, provide meaningful intervention and help people maintain the movement, confidence and independence that make a full life possible.”

Beyond the Shoe: A Complete Solution

The SQAIRZ Medical approach begins with a simple premise: you cannot effectively address a risk you have not first measured.

Through the SQAIRZ Balance & Stability Program, healthcare providers can use Kinetisense® Risk of Fall and Gait Assessment technology to perform a rapid 3D movement assessment that evaluates walking speed, stride pattern, body sway, compensatory movement and an individual’s fall-risk percentage.

Those insights help inform an individualized stability plan. The SQAIRZ clinical pathway is designed around escalating levels of intervention based on identified risk, ranging from neuromuscular education and baseline guidance for lower-risk patients to appropriate orthopedic solutions.

That includes SENTRX, purpose-built balance and stability footwear engineered with a wider natural base of support, a toe box that allows the toes to spread naturally for better balance, and a high-traction outsole that helps maintain connection with the ground; and, where appropriate, Thrive Orthopedics lateral or anterior AFO bracing. Follow-up testing and outcomes tracking allow providers to reassess patients over time.

Integrates into Clinical Care

SQAIRZ Medical is being developed around the realities of clinical adoption, patient access and reimbursement.

For patients whose assessment indicates a greater need for stabilization, the SQAIRZ clinical pathway incorporates Thrive Orthopedics AFO solutions, including pathways identified in SQAIRZ materials under L1952 and L1933. The broader program is supported with provider education, treatment-pathway guidance, documentation tools, chart-note templates and letters of medical necessity.

SQAIRZ patient materials indicate that SENTRX footwear may be covered through Medicare, depending on patient qualification and coverage. Patients may also have HSA/FSA payment options.

The goal is to create a Balance & Stability solution that can live not only in consumer commerce, but inside real patient-provider workflows.

Built with Medical Expertise

The development of SQAIRZ Medical is supported by a multidisciplinary Medical Advisory Board spanning orthopedics, podiatry, physical therapy, biomechanics, sports medicine and movement science.

The advisory group includes physicians, surgeons, podiatrists, physical therapists, researchers and biomechanics experts with experience across leading medical institutions, professional sports and clinical practice. Their role extends beyond product endorsement, helping inform clinical protocols, research priorities, provider education and the continued development of evidence-based approaches to balance and stability.

“In podiatry and sports medicine, we see every day how much the relationship between the foot and the ground influences balance, confidence and movement,” said Dr. Paul Klutts, DPM, Director of Fellowship for Kentucky and Indiana Foot and Ankle. “What is compelling about SQAIRZ Medical is that it approaches stability as a system: measure risk, create a stronger foundation at the foot and connect that intervention to ongoing clinical care. SENTRX is designed to make that foundation part of everyday life.”

“Fall risk is not a single-variable problem, and it should not be addressed with a single-variable solution,” said Dr. Larry Benz, PT, DPT, OCS, MBA, MAPP, FAPTA, Founder and CEO of Confluent Health. “The opportunity with SQAIRZ Medical is to connect objective assessment, footwear, individualized intervention and outcomes tracking in a way that can fit within the continuum of care. That kind of integrated approach can help clinicians move from reacting to falls toward identifying and addressing risk earlier.”

From Performance Footwear to Performance throughout Life

SQAIRZ Medical represents a natural expansion of the company’s original mission.

SQAIRZ was founded on the belief that performance starts where you stand. Across golf, baseball, softball and pickleball, the company has focused on the relationship between the ground, the foot, stability and human movement. SQAIRZ Medical applies that same foundational thinking to a different stage of life.

“People don’t wake up wanting a stability shoe. They want to keep doing the things they love. They want another walk with their spouse, another vacation, another birthday, another afternoon with their grandchildren. They want to remain active, vital and independent for as long as possible,” Winskowicz said. “That is what we mean by SQAIRZ FOR LIFE. From helping an athlete perform to helping someone maintain their movement and independence as they age, we want SQAIRZ to be The Foundation of Human Movement throughout every stage of life.”

About SQAIRZ

SQAIRZ is a biomechanically driven performance footwear company founded on the principle that performance starts where you stand. Through footwear engineered to enhance stability, ground connection and movement, SQAIRZ serves athletes across golf, baseball, softball, pickleball and now consumers through SQAIRZ Medical. For more information, visit SQAIRZ.com or SQAIRZMedical.com.

View original content:https://www.prnewswire.com/news-releases/sqairz-launches-sqairz-medical-302874411.html

SOURCE SQAIRZ

Continue Reading

Technology

MHK and MCG Partner to Connect Evidence-Based Clinical Guidance with Standards-Based Prior Authorization

Published

on

By

New integration to help health plans streamline prior authorization and prepare for CMS-0057-F compliance

SEATTLE, Sept. 10, 2026 /PRNewswire/ — MCG Health, part of the Hearst Health network and the industry’s source of truth for trusted clinical guidance, announces a newly certified integration with MHK, a leading healthcare technology provider and a sibling Hearst Health company. The new integration connects the MCG Path interoperability solution directly with the MHK CareProminence prior authorization workflow, helping health plans streamline authorization processes while supporting standards-based interoperability required by the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F).

The prior authorization process has historically required healthcare providers and health plans to navigate separate clinical, documentation, and administrative requirements. When required clinical information is not clearly identified at the point of request, submissions may be incomplete, resulting in requests for additional information, manual follow-up, longer review cycles, and ultimately, delayed care for members. Simultaneously, health plans seek to balance adapting their current utilization management workflows to the evolution of standards-based interoperability.

The new MHK CareProminence and MCG Path integration brings highly trusted clinical guidance and documentation requirements directly into the authorization workflow, connecting capabilities that have traditionally operated as separate steps. Using HL7® Da Vinci Project burden reduction standards – including Coverage Requirements Discovery (CRD), Documentation Templates and Rules (DTR), and Prior Authorization Support (PAS) – the integration surfaces evidence-based MCG clinical indications and structured documentation requirements at the point of a prior authorization request.

The integration is designed to help health plans:

Support evidence-based decision-making by incorporating the nationally recognized MCG care guidelines into the prior authorization workflowReduce administrative burden by helping providers identify and submit required clinical documentation earlier in the processPromote more consistent reviews by making structured clinical requirements available within existing workflowsAdvance interoperability readiness by supporting HL7 Da Vinci standards associated with CMS-0057-F API requirements that are primarily due January 1, 2027

One of the first to utilize the MHK-MCG integration will be Mountain Pacific, a multi-state nonprofit organization with a long history of innovation and healthcare quality improvement.

“We’re excited to integrate MHK CareProminence and MCG into our medical necessity review process for prior authorization as part of our continued commitment to modernizing healthcare delivery,” said Jill Alessi, Chief Executive Officer at Mountain Pacific. “By connecting trusted, nationally recognized, evidence-based clinical guidelines with clearer documentation requirements, this integration has the potential to reduce administrative burden, streamline the review process, facilitate timely care, strengthen collaboration, and support a more efficient experience for providers and their patients.”

“Prior authorization works best when clinical guidance, documentation requirements, and the authorization workflow are connected rather than operating as separate steps,” said Carol Helton, COO of MHK. “Bringing MCG’s trusted clinical guidance directly into CareProminence enables health plans to simplify that process while giving providers clearer information at the point of request. Equally important, this integration gives our customers a practical path toward the standards-based interoperability required under CMS-0057-F.”

“We’re seeing tremendous momentum for MCG Path as health plans across the country prepare for the next era of interoperable prior authorization,” said Jon Shreve, President and CEO of MCG Health. “Our partnership with MHK is a critical part of that progress, bringing the trust of MCG directly into the workflows health plans already use. Together, we’re driving more confident decisions that help patients get the right care.”

The certified MHK-MCG interoperability integration is currently available to health plans, and demonstrations can be requested via the MHK and MCG websites at mhk.com/contact/schedule-a-demo/ or mcg.com/contact-us/schedule-a-demo/.

About MCG Health

MCG, part of the Hearst Health network, is the trusted source of truth for clinical guidance in the healthcare industry. MCG combines evidence-based guidelines and analytics with artificial intelligence to guide efficient and accurate clinical decisions. MCG solutions are licensed by a vast majority of health plans, thousands of hospitals, and many state and federal government agencies to drive quality health outcomes while controlling costs. For more information, visit mcg.com.

About MHK

MHK, formerly MedHOK, is a leading provider of healthcare SaaS solutions for health plans, pharmacy benefit managers, and provider-sponsored organizations. MHK’s platforms support utilization management, case management, population health, pharmacy management, enrollment, and compliance. Headquartered in Tampa, Fla., MHK partners with payers nationwide to optimize operations, improve outcomes, and deliver superior member experiences. For more information, visit mhk.com.

About Mountain Pacific

Established in 1973, Mountain Pacific has decades of experience collaborating with healthcare professionals, consumers and communities across multiple states to deliver innovative solutions. Through federal, state and commercial funding and partnerships, Mountain Pacific brings national public health priorities to the local level to achieve better health outcomes, lower costs, greater access to high-quality care and improved patient experiences. Learn more at mountainpacific.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mhk-and-mcg-partner-to-connect-evidence-based-clinical-guidance-with-standards-based-prior-authorization-302868125.html

SOURCE MCG Health

Continue Reading

Technology

NuxGame Heads to SBC Summit Lisbon 2026 With Its Full Ecosystem and a Seat on the Compliance Stage

Published

on

By

LIMASSOL, Cyprus, Sept. 10, 2026 /PRNewswire/ — NuxGame, a B2B iGaming software provider, will take part in SBC Summit Lisbon 2026, held from Sept. 29 to Oct. 1 at the Feira Internacional de Lisboa. The team will be based at Stand A326 in Hall 1, the event’s Networking Lounge sponsored by NuxGame, where operators can sit down with senior staff from the product and commercial teams.

From Software Provider to Open Ecosystem

The timing suits where the business now stands. NuxGame began in 2018 as a software provider for operators launching their first projects, and today it runs an open ecosystem built around operator growth. Lisbon is one of the few occasions in the year when all of it can be seen in one place, by the people who would use it day to day.

What Operators Will See at Stand A326

Across the three days, the team will walk operators through the NuxGame Ecosystem in full:

An award-winning turnkey casino and sportsbook platform.

A game aggregator with 18,500+ titles from 140+ providers.

Sweepstakes-ready infrastructure.

A vetted network of partners covering CRM, payments, orchestration, and traffic.

That last part saves time. Instead of assessing vendors market by market, operators plug into partners already working in the regions they are entering, with the software underneath coming from a single provider. It is all backed by a service team whose client satisfaction has averaged 4.8 out of 5 over the past six months.

Denis Kosinsky on the Compliance Tech Stage

On Thursday, Oct. 1, NuxGame Chief Product Officer Denis Kosinsky will join the panel “Closing the Loopholes: How to Combat Bonus Abuse” on the Regulation & Compliance stage, part of the summit’s new Compliance Tech track. The session looks at how operators can recognize evolving patterns of bonus exploitation and keep promotional spend flowing to the players it was designed for.

“A bonus budget is one of the most powerful growth tools an operator has, and it works best when the money reaches genuine players. The instinct is to tighten the rules for everyone, but that’s like locking the whole building because one window doesn’t shut. Better to find the window. When you can see clearly how a promotion is actually being used, you close that one gap and leave the offer generous for everybody else.”

— Denis Kosinsky, Chief Product Officer at NuxGame

Book a Meeting in Lisbon

“Lisbon is where a lot of operators decide what their next year looks like. We wanted a space where those conversations can happen properly, with the platform, the content, and the partner network all in the room at once. Twenty minutes with the right people will tell you more than three months of comparing suppliers on paper.”

— Daniel Heywood, Chief Executive Officer at NuxGame

Operators, affiliates, and partners attending the summit can book a meeting with the NuxGame team in advance, or stop by Stand A326 in Hall 1 on any of the three days.

About NuxGame

NuxGame is a B2B iGaming company founded in 2018 that has grown from a software provider into an open ecosystem for operator growth. It combines an award-winning casino and sportsbook platform, a game aggregator with 18,500+ titles from 140+ providers, sweepstakes-ready infrastructure, and a vetted network of partners covering CRM, payments, orchestration, and traffic, supporting 100+ operators worldwide as they launch, scale, and enter new markets. In 2026, NuxGame was named Casino Platform of the Year at the iGaming News Awards. Visit https://nuxgame.com/ for more information and inquiries.

Media Contact: Yanina Kaplya, CMO at NuxGame, info@nuxgame.com

Original Source: https://nuxgame.com/blog/nuxgame-sbc-summit-lisbon-2026

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuxgame-heads-to-sbc-summit-lisbon-2026-with-its-full-ecosystem-and-a-seat-on-the-compliance-stage-302875384.html

SOURCE NuxGame

Continue Reading

Trending